Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Olfa Derbel

Showing results (21-30 of 24) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 24 results.
Gynecologic Oncology|October 13, 2019
Clinical factors associated with prolonged response and survival under olaparib as maintenance therapy in BRCA mutated ovarian cancersS Intidhar Labidi-Galy, Thibault de La Motte Rouge, Olfa Derbel, et al.
JNCI Cancer Spectrum|December 14, 2024
Improving real-world evaluation of patient- and physician-reported tolerability: niraparib for recurrent ovarian cancer (NiQoLe)Florence Joly, Fernando Bazan, Delphine Garbay, et al.
Nature Communications|July 16, 2024
Immunomic longitudinal profiling of the NeoPembrOv trial identifies drivers of immunoresistance in high-grade ovarian carcinomaOlivia Le Saux, Maude Ardin, Justine Berthet, et al.
The Lancet. Oncology|October 2, 2022
Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trialFrançois-Clément Bidard, Anne-Claire Hardy-Bessard, Florence Dalenc, et al.
Pageof 3

Showing results (21-30 of 24) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 24 results.
Gynecologic Oncology|October 13, 2019
Clinical factors associated with prolonged response and survival under olaparib as maintenance therapy in BRCA mutated ovarian cancersS Intidhar Labidi-Galy, Thibault de La Motte Rouge, Olfa Derbel, et al.
JNCI Cancer Spectrum|December 14, 2024
Improving real-world evaluation of patient- and physician-reported tolerability: niraparib for recurrent ovarian cancer (NiQoLe)Florence Joly, Fernando Bazan, Delphine Garbay, et al.
Nature Communications|July 16, 2024
Immunomic longitudinal profiling of the NeoPembrOv trial identifies drivers of immunoresistance in high-grade ovarian carcinomaOlivia Le Saux, Maude Ardin, Justine Berthet, et al.
The Lancet. Oncology|October 2, 2022
Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trialFrançois-Clément Bidard, Anne-Claire Hardy-Bessard, Florence Dalenc, et al.
Pageof 3